|
|
 |
My research has focused on clinical trials in the hematologic malignancies.
I have studied the pharmacokinetics of cytarabine in the spinal fluid when given
intravenously and I identified renal function as the most important factor in predicting
central nervous system toxicity from cytarabine. I was the campus PI on a clinical trial
of vaccine therapy for acute myeloid leukemia. I participated in UCSF-initiated trials for
treating adults with AML, lymphoma, and ALL, some of which involved stem cell transplantation.
I participate in clinical protocols for the national group called Cancer and Leukemia Group B
(CALGB). I was national PI on CALGB 59909, a trial for treating mantle cell
lymphoma and involving stem cell transplantation.
Selected Publications
Bright R, Eisendrath S, Damon L (2001). A case of factitious aplastic anemia. Int J Psychiatry Med 31: 433-441.
Damon L, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, Linker CA. (2004). Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA).
A randomized study of etoposide schedule. Cancer Chemotherapy Pharmacol 53: 468-74.
Damon L, Rugo H, Tolaney S, Navarro W, Martin III T, Ries C, Case D, Ault K, Linker C. (2006) Cytoreduction of
lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Biol Blood Marrow Transplant 12: 316-24.
Mintz PD, Neff A, Mackenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS,
Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J,
Lin JS, Corash L, Conlan MG. (2006) A randomized, controlled Phase III trial of therapeutic plasma
exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to
untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 46(10):1693-704.
Information last updated September 2007
|
|
|
